# Low-dose Evaluation of Aspirin After STEMI Patients With PCI: A Multicenter, Double-blind, Randomized Controlled Clinical Trial

> **NCT06756945** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Beijing Anzhen Hospital** · enrollment: 3612 (estimated)

## Conditions studied

- ST-elevation Myocardial Infarction (STEMI)

## Interventions

- **DRUG:** aspirin 50 mg once daily (one 50 mg aspirin tablet plus one matching placebo tablet) plus ticagrelor 90 mg twice daily
- **DRUG:** aspirin 100 mg once daily (two 50 mg aspirin tablets) plus ticagrelor 90 mg twice daily

## Key facts

- **NCT ID:** NCT06756945
- **Lead sponsor:** Beijing Anzhen Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 3612 (ESTIMATED)
- **Last updated:** 2025-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06756945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06756945, "Low-dose Evaluation of Aspirin After STEMI Patients With PCI: A Multicenter, Double-blind, Randomized Controlled Clinical Trial". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06756945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*